12:00 AM
Sep 21, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

RTL1000: Phase I data

A double-blind, placebo-controlled, U.S. Phase I trial in 34 patients with relapsing, remitting and secondary multiple sclerosis established an undisclosed MTD for IV RTL1000. The company...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >